Fate Therapeutics, Inc.FATENASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +58.13% | +10.98% | -15.38% | -71.84% | -43.36% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | -7.02% | -43.36% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.48% | +19.45% | +17.08% | +0.90% | +1.04% |
| Weighted Average Shares Diluted Growth | +19.48% | +19.45% | +17.08% | +0.90% | +1.04% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +168.34% | +93.81% | +180.42% | +33.11% | -83.47% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -8.98% | -12.94% | -30.04% | -29.72% | -30.57% |
| Book Value per Share Growth | -24.71% | -27.57% | -42.19% | -34.75% | -36.07% |
| Debt Growth | -5.69% | -17.65% | -18.36% | -19.12% | -19.94% |
| R&D Expense Growth | +1.09% | +5.64% | -9.34% | -20.73% | -25.43% |
| SG&A Expenses Growth | +9.78% | -14.90% | -33.96% | -33.66% | -48.86% |